Finally, in a recent study, since human SyS tumors, compared to other translocated sarcomas, demonstrate increased expression of BCL2 and decreased expression of NOXA, the endogenous inhibitor of MCL-1, the resulting increased activity of MCL-1 pro-survival protein was identified as responsible for venetoclax resistance in SyS. Here, MCL1 is linked to sarcoma.